

AVICANNA™

A leader in biopharmaceutical advancements
with natural cannabinoids

June 2020

avicanna.com

TSX: AVCN
OTCQX: AVCNF
FSE: ONN



Forward-Looking Statement

This document and the material contained herein are confidential and are not to be disclosed to the public. This is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. Certain information contained herein and certain oral statements made are forward-looking and relate to Avicanna Inc.'s ("Avicanna") business strategy, product development, timing of product development, events and courses of action. Statements which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, outlook, milestones, expectations or intentions regarding the future including words or phrases such as "anticipate," "objective," "may," "will," "might," "should," "could," "can," "intend," "expect," "believe," "estimate," "predict," "potential," "plan," "is designed to" or similar expressions suggest future outcomes or the negative thereof or similar variations. Forward-looking statements may include, among other things, statements about anticipated dates for revenue recognition; anticipated dates for product launches; our plans for future products and enhancements of existing products; designs for future product packaging; expected completion dates for clinical trials and product development; expected results of clinical trials; the granting of any certifications, licenses, or registrations; our future growth strategy; our future intellectual property, research and development, product formulations and business lines; intended quality standards of our joint venture with Sigma Analytics; each of our expected upcoming milestones; and our anticipated trends and challenges in the markets in which we operate. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which Avicanna will operate in the future, including the demand for our products, anticipated costs and ability to achieve goals, expected outcomes for clinical trials, the timely completion of research and development initiatives and the price of cannabis and cannabis related products. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect.

Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to, business, economic and capital market conditions; the ability to manage our operating expenses, which may adversely impact our financial condition; our ability to remain competitive as other better financed competitors develop and release competitive products; regulatory uncertainties; weather patterns; market conditions and the demand and pricing for our products; the demand and pricing of cannabis and cannabidiol ("CBD"); security threats, including a loss/ theft of proprietary technology; our relationships with regulatory bodies, our customers, distributors and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers' needs; our ability to attract, retain and motivate qualified personnel; competition in our industry; our ability to maintain technological leadership; the impact of technology changes on our products and industry; our failure to develop new and innovative products; our ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; the impact of intellectual property litigation that could materially and adversely abet our business; our ability to manage working capital; our dependence on key personnel; the severity, duration and effects of the pandemic related to the novel strain of coronavirus that emerged in December 2019 in Wuhan, China ("COVID-19") on our business, including potential impacts of COVID-19 on our distribution and supply channels and additional risk factors included elsewhere in Avicanna's public disclosure, including but not limited to, under the heading "Risk Factors" in Avicanna's long-form prospectus dated July 8, 2019, in Avicanna's annual information form dated April 15, 2020 and in Avicanna's Management's Discussion & Analysis of Financial Condition for the Three Months Ended March 31, 2020. Although Avicanna has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended.

Avicanna is an early stage company with a short operating history; and it may not actually achieve its plans, projections, or expectations. Important factors that could cause actual results to differ materially from Avicanna's expectations include, consumer sentiment towards Avicanna's products and cannabis and cannabis related technology generally, litigation, global economic climate, equipment failures, increase in operating costs, decrease in the price of cannabis and CBD, security threats including a loss or theft of intellectual property, adverse medical findings, government regulations, loss of key employees and consultants, additional funding requirements, changes in laws, technology failures, competition, failure of counter-parties to perform their contractual obligations, delays or unexpected expenditures in completion of clinical trials, unexpected delays in the commercialization of products and the severity, duration and effects of COVID-19. Forward-looking statements contained in this presentation are as of the date of this presentation and, except as required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this presentation. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation.

Financial & Third Party Information

All financial information included in this document is unaudited. There is a material risk that the audited financial results will differ significantly from the unaudited financial information presented herein.

Avicanna disclaims any intention or obligation to update or revise any forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, unless required pursuant to applicable securities law. Readers are cautioned that the forward-looking statements contained in this document should not be used for purposes other than for which it is disclosed herein. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

Certain information contained herein is based on, or derived from, information provided by independent third-party sources. Avicanna believes that such information is accurate and that the sources from which it has been obtained are reliable. Avicanna cannot guarantee the accuracy of such information, however, and has not independently verified the assumptions on which such information is based. Avicanna does not assume any responsibility for the accuracy or completeness of such information.




Corporate Overview


A leader in biopharmaceutical advancements with natural cannabinoids

Avicanna is a Canadian vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global market place.


Avicanna's 3 advanced product categories:



Consumer Retail Products
Commercial



Medical Products
Commercial



Pharmaceutical Pipeline
In Clinical Development



Corporate Overview

Delivering cannabinoid products through science



Advanced R&D, pre-clinical and clinical platform

- ▶ 20+ scientists and clinicians housed in four federally licensed cannabinoid research laboratories
- ▶ Collaborations with world class academic and clinical institutions including the University of Toronto
- ▶ Optimized proprietary methodologies in breeding, cultivation, extraction, formulation development, clinical development and analytical testing over the past 4 years



Diversified and high margin income streams

- ▶ Comprehensive commercial portfolio and pipeline of products across consumer retail products, medical and pharmaceutical segments
- ▶ Multi-national operations and international sales from low-cost inputs to advanced finished products
- ▶ De-risked and diversified revenue streams ranging from seeds, genetics, cannabinoid API, bulk formulations, finished products and licensing of IP



World-class & low-cost vertical integration

- ▶ Two Colombian subsidiaries with a combined cultivation footprint of 480,000 sq. ft. and annual capacity of 30,000 kg of low-cost biomass and industrial extraction capacity
- ▶ Organic and sustainable cultivation practices with USDA National Organic Program certification ranked highest amongst global cannabis companies in the SAM Corporate Sustainability Assessment issued by S&P Global



Setting the standards
in cannabinoid R&D and
advanced product offerings

4+ years of cannabinoid research & development

Dr. Frantz Le Devedec and Dr. Justin Grant at Avicanna's R&D headquarters at the MaRS Discovery District in Toronto



Global Leader in Advanced Cannabinoid Research and Pharmaceutical Development



R&D headquarters at JLABS @ Toronto in the MaRS Discovery District

- ▶ Cannabis Research Licence issued by Health Canada at Avicanna central R&D lab at the Johnson & Johnson Innovation Centre, where Avicanna's scientists conduct research in collaboration with world-class researchers and institutions



Advanced scientific platform, established platform and team of 20+ Scientists and Clinicians

- ▶ Working across federally licensed R&D laboratories for cannabinoid research and leveraging from optimized proprietary methodologies in extraction, formulation development, clinical development and analytical testing over the past 4 years



Exclusive Collaboration Agreement with Dr. Christine Allen's Research Group ("CARG") at the University of Toronto

- ▶ A leader within the global pharmaceutical field of drug delivery, Dr. Allen and her team within the Faculty of Pharmacy collaborate on Avicanna's pharmaceutical product development and pre-clinical development



Consumer retail products CBD derma-cosmetics





Pura Earth

Consumer retail products: CBD derma-cosmetics

- ▶ Unique line of premium & natural skin care products utilizing the benefits of CBD with synergistic natural ingredients
- ▶ Fully developed and commercial line of products offered both in retail and e-commerce
- ▶ A data-backed approach as the only known CBD cosmetics line of products with completed clinical results
- ▶ **PRODUCT LAUNCH EXPECTATIONS*:**
 - Colombia 4Q19
 - EU 2H20
 - USA 2H20
 - Canada 2H20

*The product launch expectations are conditional upon regulatory approvals.





Completed Cosmetic Clinical Studies

Intensive Moisturizing Cream



Overview

- ▶ Study Design: 1 arm, n=49

End Points

- ▶ Primary endpoint: Hydrating effect
- ▶ Secondary endpoints: Sebum production, sensory evaluation (oily skin feeling), lesions evaluation (acne), tolerability/acceptability, QoL

Results

- Sustained hydration*
- Improves the perceived look of oily skin
- Improved perceived appearance of the skin
- Doesn't exacerbate (irritate) oily skin
- Hydrates oily skin



Clear Skin Gel



Overview

- ▶ Study Design: 1 arm, n=49

End Points

- ▶ Primary endpoint: Hydrating effect
- ▶ Secondary endpoints: Viscoelasticity, skin softness, erythema, TEWL, tolerability/acceptability

Results

- ▶ Sustained hydration*
- ▶ No perceived greasy after feel



Anti-aging Serum



Overview

- ▶ Study Design: 1 arm, n=48

End Points

- ▶ Primary endpoint: Evaluation (visual) in the improvement of fine lines & dark spots associated with aging
- ▶ Secondary endpoints: Viscoelasticity, hydrating effect, TEWL, tolerability/acceptability & satisfaction

Results

- ▶ Sustained hydration*
- ▶ Fast hydration
- ▶ Maintains a normal and healthy pH of the skin



*Clinically tested that applying cream twice per day results in sustained hydration.



Medical products

CBD & THC Medical Cannabis 2.0 Products





RHO Phyto – CBD & THC Medical Cannabis 2.0 Products

Pre-clinical data demonstrating enhanced bioavailability in collaboration with University of Toronto

- ▶ Medical only – access through healthcare practitioners
- ▶ Pharmaceutical sales approach




Formulations optimized
in collaboration with
CARG at the University
of Toronto



Rigorous *in vitro* analysis
to ensure product
stability, precise delivery,
and consistency



Further validation
and optimization in
pre-clinical and
pharmacokinetic studies



Innovative & advanced
delivery mechanisms
designed to be discreet
and easy to administer





RHO Phyto – CBD & THC Medical Cannabis 2.0 products Distributed exclusively through Medical Cannabis by Shoppers™

Shoppers Drug Mart is Canada's leading drug store retailer with more than 1,300 pharmacist-owned locations from coast to coast.

- ▶ Strategic manufacturing of the RHO Phyto branded formulations and products in partnership with MediPharm Labs

About Medical Cannabis by Shoppers™

Medical Cannabis by Shoppers™ provides access to high-quality cannabis through online ordering. Shoppers is leading the way by connecting patients with a variety of medical cannabis options and guiding product choice through the advisors and pharmacists on the Shoppers Cannabis Care team. Registered patients benefit from convenience, selection, and support from trained professionals.



Note: The product mock-ups that appear on this page are not indicative of final products that may be marketed and sold.




RHO Phyto - Pre-clinical Results




Soft Gel Capsules: High Bioavailability

Designed for controlled dosage and delivery




Sublingual Spray: Rapid Onset

Sublingual formulation



Topical Cream: Local Delivery

Topical cream formulation designed for local application




*All pre-clinical animal studies conducted at the University of Toronto with Health Canada approvals.



Pharmaceutical pipeline

Indication-specific products with a focus on
Neurology, Pain and Dermatology





Pharmaceutical Pipeline and Target Therapeutic Indications

Pharmaceutical product pipeline following the traditional drug discovery and development process for eventual submission to the applicable government agencies, such as Health Canada, FDA (United States) and INVIMA (Colombia).



Dermatology

- ▶ Epidermolysis Bullosa
 - ▶ Eczema
 - ▶ Acne



Psychiatry

- ▶ Anxiety and Depression
- ▶ Sleep disorders
- ▶ Opioid addiction




Neurology

- ▶ Epilepsy
- ▶ Parkinson's Disease
- ▶ Multiple Sclerosis



Pain

- ▶ Chronic pain
- ▶ Neuropathic pain
- ▶ Arthritis



Oncology

- ▶ Palliative care



Clinical Trials Pipeline

All Clinical Trials	Pre-Clinical	Protocol Development	Protocol Established	Ethics Approval	Clinical Study
Cosmetic Trials					
Eczema-prone Skin					
Acne-prone Skin					
Anti-Aging					
Oral Care Mouthwash					
Real-World Evidence (RHO Phyto)					
Opioid Sparing				Pending Approval	
Pain related to Inflammatory Bowel Disorder					
Cognition & balance in Parkinson's Disease					
Pharmaceutical Trials					
Epidermolysis Bullosa*					Phase II Pending
Prevalance of Neuropathic Pain in Sickle Cell Disease					
Neuropathic Pain in Sickle Cell Disease*					
Eczema*					
Arthritis					

*Phase I studies not required for this product; Pending regulatory approval.



World-class vertical integration

From seeds to patients

Photo of Santa Marta Golden Hemp's facility in Santa Marta, Colombia.





World-Class & Low-Cost Vertical Integration



Sustainable and economical cultivation

- ▶ 2 fully licensed and commercial majority-owned subsidiaries in Santa Marta, Colombia
- ▶ Organic and sustainable cultivation USDA National Organic Program certification for hemp
- ▶ Annual capacity of 30,000 kilograms through 480,000 square feet of combined cultivation space



Extraction, purification, and supply of API

- ▶ GMP-compliant and industrial-scale extraction and isolation capacity
- ▶ In-house QC lab to ensure the API meets EU and US pharmacopeia standards



GMP Manufacturing

MediPharmLabs

- ▶ Strategic manufacturing and intellectual property licensing agreement for medical cannabis and pharmaceutical products
- ▶ GMP certification by the Therapeutic Goods Administration (Australia)

Altea Farmaceutica S.A.


- ▶ Exclusive contract manufacturing agreement for pharmaceutical, medical cannabis, and derma-cosmetic products
- ▶ GMP certification by Health Canada, ANVISA (Brazil) and INVIMA (Colombia)





Avesta Genetica

Genetics and commercial
seeds program



AVESTA
GENETICA



Avesta Genetica

Genetics and commercial seeds program

- ▶ 30 federally registered commercial genetics of hemp and cannabis in Colombia expressing CBD, THC, CBG and other rare cannabinoids
- ▶ A scientific approach to breeding and optimization in collaboration with University of Guelph
- ▶ A rich catalogue of 100's of rare genetics from around the world that have been specially selected for the Avesta Genetica program
- ▶ Commercial seeds and genetics available for international markets with the first ever export of seeds out of Colombia in Q2 2020





Aureus **Santa Marta**

Cannabinoid formulations,
active pharmaceutical ingredients








Aureus Santa Marta

Cannabinoid formulations and active pharmaceutical ingredients

Utilizing proprietary extraction and purification processes in line with GMP standards and full quality controls meeting Health Canada, European Pharmacopeia, and US Pharmacopeia Standards.

Product Offerings: CBD, THC, and CBG

- ▶ Custom and white / private label formulations
- ▶ Whole plant crude oils (60-70% purity)
- ▶ Cannabinoid distillate (80-95% purity)
- ▶ Isolated and purified cannabinoids (98-99% purity)
- ▶ Cosmetic and food grade CBD/CBG





Financial Highlights

Common Shares: 26,387,444*

- ▶ Fully diluted: 31,969,980
- ▶ **Free Float: 6,613,400**
- ▶ Director Escrow: 7,168,302**
- ▶ Officers Escrow: 540,743**
- ▶ 39 Month Escrow: 2,209,450***

Market cap \$46.2M, at market close on June 1, 2020 (\$1.75)****

**Last Financing (April 2020):
\$2.56M | \$0.80 per share**

*Number of common shares issued and outstanding as of June 1, 2020. **10% to be released on July 1, 2020 for Director Escrow (10% released on January 1, 2020 for Officers Escrow) and 15% to be released every six months thereafter. Max 5,000 shares per week can be sold for 1 year from initial 10% release for both Director and Officers Escrow. ***10% released in October 2019 and 15% to be released every six months thereafter. ****www.bloomberg.com.

Industry Peer Analysis as of June 1, 2020****

CANNABINOID PHARMACEUTICALS

GW Pharmaceuticals:

NASDAQ: GWPH | \$3.86B (USD) Market Cap

Zynerba Pharmaceuticals Inc:

NASDAQ: ZYNE | \$137.7M (USD) Market Cap

Lexaria Bioscience Corp:

LXX.CN | \$36M Market Cap

Cardiol Therapeutics Inc.:

TSX: CRDL | \$71.7M Market Cap

COLOMBIAN CULTIVATION

PharmaCielo Ltd.:

TSXV: PCLO | \$93.9M Market Cap

Khiron Life Sciences Corp:

TSXV: KHRN | \$84.8M Market Cap

Clever Leaves

(Private) | \$250M Market Cap



**Experienced and accomplished management team,
world-class scientific collaborations**



Executive Management Team

Aras Azadian, M.Mgmt

Chief Executive Officer

Utilizing his extensive senior management experience in both financial and bio-technology sectors, Aras co-founded Avicanna with the vision of establishing a bio-pharmaceutical company with a strict focus on medical and pharmaceutical applications of cannabinoids. His expertise experience in the biotechnology industry have been integral to Avicanna's thought leadership pertaining to R&D and clinical development. Since 2016 Aras has successfully led a team of executives, scientists, and medical professionals across several countries with the vision of vertical integration and a strong company focus on quality controls, scientific vigour and competitive advantages. Aras holds a Bachelor of Economics degree from York University and an International master's in management degree from EADA Business School in Barcelona, Spain.

Setu Purohit, JD, ICD.D

President and Chief Legal Officer

Experienced in complex corporate and legal strategy, as well as contract negotiations, Setu's unique expertise as a lawyer and an entrepreneur have been central to Avicanna's structure and key global partnerships. As the executive lead for Avicanna's Initial Public Offering (IPO) process, Setu encompasses the qualities of an adaptive strategic leader equipped with market awareness, business acumen and an in-depth understanding of Avicanna's long term objectives. With a high regard for best practices, our co-founder Setu, spearheads the company's regulatory navigation with a vision specific to the pursuit of partnerships and commercialization opportunities. Setu holds a Bachelor of Commerce degree from the University of Ottawa and Juris Doctorate (JD) degree from the University of Western Ontario.

Dave Sohi, CPA, CA, CBV

Chief Financial Officer

Dave has been responsible for all financial operations at Avicanna since inception. A pragmatic financial leader, Dave has wide-ranging experience in financial management, business leadership, corporate strategy, mergers and acquisitions, and valuation services. His extensive experience with RSM Richter's and Ernst and Young's Transaction Advisory Practices has equipped him with the acumen and vision to deliver exceptional strategic direction, streamlined financial and procedural policies and create monitoring and accountability systems. Dave spearheads the responsibility for the complete and accurate preparation of all Avicanna teams and subsidiaries for Initial Public Offering (IPO). Dave has obtained his Chartered Accountant and Chartered Business Valuator designations and has earned a Bachelor of Commerce degree from Queen's University.

Ivana Maric

Executive Vice President, Marketing

Leading the company's marketing operations since inception, Ivana has championed the development, launch and management of all Avicanna's brands and product lines globally. A trailblazer with significant experience in traditional and digital media platforms, advertising, brand development and awareness across several sectors, Ivana utilizes both her previous experience and her thorough comprehension of the evolving landscape of the cannabis industry, it's trends and challenges. Her former experience as the Director of Marketing for Ophiuchus Consulting Group and leading numerous marketing efforts and brand launches for start-up companies has been central to Avicanna's exponential and continued growth. Ivana has a Bachelor of Commerce degree in Marketing Management from Ryerson University.

Dr. Amza Ali, MD, FRCP, MBA

Chief Medical Officer

A 2019 global Ambassador for Epilepsy and current President of the Epilepsy Society of the Caribbean, Dr. Amza Ali is a world renown neurologist and epileptologist who is leading all of Avicanna's clinical development projects. Committed to improving the quality of care and welfare of patients with neurological disorders, especially epilepsy, Dr. Ali obtained his initial medical training from the University of West Indies (UWI). He is a Specialist certified in Neurology by the Royal Colleges of Physicians of the UK. Amongst many distinctions, he holds a Master of Business Administration (MBA) degree from the Rotman School of Management at the University of Toronto. Dr. Ali has received prestigious international and global awards for his work in the field of epilepsy and neurology and has authored many publications in basic science and clinical medicine, with a principal focus on epilepsy. He is a Fellow of the American Academy of Neurology as well as a Fellow of the American Epilepsy Society.

Dr. Justin Grant, PhD, MBA

Executive Vice President, Scientific Affairs

With over fifteen years of experience in leading pharmaceutical drug development, Dr. Justin Grant offers the expertise required for the growth and development of Avicanna's scientific divisions. His experience includes nearly twelve years of leadership roles in some of Canada's top research and medical institutions such as UHN. His academic accomplishments include a PhD in Pharmaceutical Sciences at the University of Toronto where he published and patented several sustained drug release formulations. In addition, Dr. Grant completed his Executive Master of Business (MBA) from Rotman School of Management at the University of Toronto. Dr. Grant has been part of the Avicanna Scientific Advisory Board since 2016, where he held title of Chair prior to joining the company full time in 2019.

Lucas Nosiglia, MFin

Chief Agricultural Officer

A seasoned entrepreneur and executive with experience across Europe, North America and South America, Lucas has been at the forefront of Avicanna's Latin America (LATAM) operations since the company's inception in 2016. His innovative and transformative approach in navigating the cannabis industry and his former involvement in management consulting, finance and health care have been invaluable in establishing and operating the company's Colombian subsidiaries including two fully operational cultivation projects. Lucas' experience from working at Deloitte along with his leadership values are at the core of his success in leading Avicanna's largest teams. Lucas graduated with an Honours degree from Faculty of Economics of University of Buenos Aires and holds a Masters degree in Finance from EADA in Barcelona Spain.



Board of Directors

Aras Azadian, M.Mgmt

Chief Executive Officer

Setu Purohit, JD, ICD.D

President and Chief Legal Officer

Dr. Chandrakant Panchal

Chairman

Dr. Panchal has been the Chief Executive Officer of Axcelon Biopolymers Corp. since 2008, has authored over seventy scientific papers, holds several patents in oncology, diagnostics, biopolymers and microbiology, and is an Adjunct Professor in Chemical and Biochemical Engineering at the University of Western Ontario. Dr. Panchal currently sits on the board of directors of both an oncology company known as Medicenna Therapeutics Corp. (MDNA), and Canadian Oil Recovery and Remediation Inc. (CVR) as well as Pure Global Cannabis Inc. (PURE). Dr. Panchal holds a Master of Science degree in Molecular Biology and a Ph.D. in Biochemical Engineering from the University of Western Ontario.

David Allan White

Director

Mr. White is a director and chair of audit committees of several Toronto Stock Exchange ("TSX") and NASDAQ companies. Mr. White has held several senior financial positions with John Labatt Limited, Lawson Marden Group Inc. and Laidlaw Inc. and most recently as Chief Executive Officer of TransCare Inc., a medical transportation company and as President and Chief Executive Officer of Student Transportation of America, a TSX listed company. In addition to sitting on Avicanna's Board of Directors and chairing the Corporation's audit committee, Mr. White has also been a corporate director and business consultant for FirstCall Services, a private holding company and advisory firm, since 2012. Mr. White has been a Canadian Chartered Accountant since 1978 and holds a Master of Business Administration degree from the University of Toronto.

Benjamin Leavenworth

Director

Mr. Leavenworth has more than 20 years' experience in international business, with a focus on Latin America. Mr. Leavenworth is currently the Chief Strategy Officer of Afina International LLC ("Afina"), a specialist advisory and finance firm, and also serves as Honorary Consul of Chile for Pennsylvania, Delaware, and southern New Jersey. Prior to co-founding Afina in 2011, Mr. Leavenworth founded and ran the Chispa Group, an international consultancy with a focus on mining, energy, agriculture, and government projects across Latin America. He also serves as president of the board of Pata Foods, a leading organic baby food producer, and as a director on the boards of the Chilean & American Chamber of Commerce, Global Independence Center, Pan America Associations, and the Consular Corps Association of Philadelphia.

Giancarlo Davila Char

Director

Mr. Char has experience with sustainable and organic cultivation and production of industrial scale palm oil as well as other agriculture crops such as avocados and coffee beans. In 2017, Mr. Char went on to lead a new branch of his family's business which is dedicated to producing private label oils for national distribution in supermarkets across Colombia. This business unit reached USD\$30,000,000 in sales in 2018. Mr. Char holds a Bachelor of Science in Business Administration from Northeastern University.

Janet Giesselman

Director

A Corporate Director at: Ag Growth International Inc. Omnova Solutions Inc. Twin Disc, Incorporated and at McCain Foods Limited, where she serves as Chair of the Environmental Health & Safety Committee as well as on the Audit and the Compensation and Management committees. Ms. Giesselman retired as the President and General Manager of Dow Oil & Gas, a business unit of The Dow Chemical Company, and has over 30 years of U.S. and international agriculture, energy and specialty and commodity chemicals industry experience in U.S., Europe, Latin America, the Middle East and Asia. Ms. Giesselman holds a B.Sc., Biology from Pennsylvania State University and a Masters in Plant Pathology from the University of Florida.




Senior Scientific Team

Senior scientific team

- ▶ **Dr. Frantz Le Devedec, PhD**
Senior Vice President, Research & Development
- ▶ **Dr. Carlos Maldonado, MD**
Senior Vice President, Clinical Development
- ▶ **Roland Alvarez**
Senior Vice President, Technical Operations
- ▶ **Samantha Watt, MSc**
Vice President, Scientific Affairs
- ▶ **Karolina Urban, MSc**
Medical Programs Director
- ▶ **Dr. Pauric Bannigan, PhD**
Senior Formulation Scientist
- ▶ **Dr. Lautaro Bracco, PhD**
Scientific Director (LATAM)
- ▶ **Dr. Clara Lemus, MD**
Medical Programs Coordinator (LATAM)

World-class scientific and clinical collaborations

- ▶ University of Toronto, Leslie Dan Faculty of Pharmacy, Dr. Christine Allen Research Group
- ▶ The Hospital for Sick Children, Pediatric Dermatology
- ▶ The University Health Network (UHN), Toronto General Hospital
- ▶ University of Guelph, Ontario Veterinary College
- ▶ Centro de Atencion e Investigacion Medica CAIMED S.A.S.
- ▶ University of The West Indies (UWI), The Sickle Cell Unit





Major Milestones

3Q19

- ✔ IPO on the TSX senior exchange as an R&D issuer
- ✔ Canadian Cannabis Research Licence issued at MaRS Discovery District, Toronto
- ✔ First export of cannabinoids for R&D purposes from Colombia to Canada
- ✔ Commencement of clinical studies on 3 Pura Earth products by CAIMED

4Q19

- ✔ USDA National Organic Program certification for hemp
- ✔ Retail and e-commerce launch of Pura Earth in Colombia
- ✔ First commercial exports of CBD API's out of Colombia
- ✔ Phase 1 combined cultivation capacity of 480,000 sq. ft. at SMGH and Sativa Nativa

1H20

- ✔ Agreement with Medical Cannabis by Shoppers, a subsidiary of Shoppers Drug Mart Inc., to distribute Avicanna's RHO Phyto and Pura Earth products across Canada
- ✔ Completion of clinical studies on 3 Pura Earth products by CAIMED
- ✔ Industrial-scale production of CBG dominant cannabis seeds and export authorization
 - ▶ Export of CBG dominant seeds into the US

2H20

- ▶ Commencement of phase IIa Epidermolysis Bullosa trials at the Hospital for Sick Children
- ▶ First export of THC and finished Rho Phyto products out of Colombia
- ▶ Commercial launch of RHO Phyto and Pura Earth in Canada with Medical Cannabis by Shoppers
- ▶ Retail and e-commerce launch of Pura Earth in the UK and US
- ▶ Commencement of opioid sparing study with University Health Network in Toronto
- ▶ In Colombia, launch of RHO Phyto products under compound pharmacy model (magistral) & phytotherapeutic registration of specific RHO Phyto products
- ▶ Launch of RHO Phyto products in the UK
- ▶ GMP certification for extraction

Expected Upcoming Milestones*

*Expected Upcoming Milestones projections are conditional upon regulatory approvals.



AVICANNA™

IR@avicanna.com